DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20160478

Anti-Müllerian hormone and response to ovulation induction with clomiphene citrate in women with polycystic ovary syndrome

Mohamed S. Sweed, Osama S. El-Kady, Eman A. AbdElSalam, Mohammed M. Mostafa

Abstract


Background: Anti-Müllerian hormone (AMH) is suggested as an important marker for women with polycystic ovary disease (PCOS). Several studies have found serum level of AMH correlate well to ovarian response to ovulation induction in women with PCOS. This study was conducted to assess the relationship between AMH in women with PCOS and response to ovulation induction with clomiphene citrate.

Methods: Prospective observational cohort study conducted at Ain-Shams university maternity hospital from February 2013 to February 2014. 100 women with PCOS were recruited from the infertility outpatient clinic. Serum AMH levels were measured by enzyme linked immunosorbent assay in the early follicular phase (days 3-5). Ovulation induction by clomiphene citrate was started on day 5 as 50 mg daily tablet for 5 days. Ovulation was documented by transvaginal ultrasonography and women who failed to ovulate till day 35 were considered anovulatory.

Results: 72 women ovulated within 12 to 33 days of the menstrual cycle, while 28 had undetectable ovulation till day 35. The median serum AMH level was significantly higher in women with failed ovulation [4.05 ng/mL (3.7 - 4.4)] than in ovulating women [2.7 ng/mL (1.9 - 3.1)] (p<0.001). Receiver-operating characteristic (ROC) curve analysis found the best cutoff value of AMH for prediction of successful ovulation ≤3.6 ng/mL (sensitivity = 97.2%, specificity = 82.1%).

Conclusions: Anti-Müllerian hormone is a very useful predictor of poor responders to clomiphene citrate among women with polycystic ovary disease.

Keywords


Anti-Müllerian hormone, Anovulation, Clomiphene citrate, Polycystic ovary disease, Poor responders

Full Text:

PDF

References


Battaglia C. The role of ultrasound and Doppler analysis in the diagnosis of polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2003;22(3):225-32.

Seow KM, Lin YH, Hwang JL, Wang PH, Ho LT, Lin YH. Expression levels of haem oxygenase-1 in the omental adipose tissue and peripheral blood mononuclear cells of women with polycystic ovary syndrome. Hum Reprod. 2011;26(2):431-7.

Azziz R, Adashi EY. Stein and Leventhal: 80 years on. Am J Obstet Gynecol. 2015.

Froment P, Touraine P. Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS). PPAR Res. 2006:73986.

La MA, Bertucci E, Giulini S, Tirelli A, Malavasi B, Volpe A. [Ovulation induction in anovulatory women]. Minerva Ginecol. 2006;58(6):489-97.

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.

Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst Rev. 2000;(2):CD000087.

Ghobadi C, Nguyen TH, Lennard MS, Amer S, Rostami-Hodjegan A, Ledger WL. Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertil Steril. 2007;87(3):597-602.

Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305-9.

Itman C, Mendis S, Barakat B, Loveland KL. All in the family: TGF-beta family action in testis development. Reproduction. 2006;132(2):233-46.

Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(3):941-5.

El-Mazny A, Abou-Salem N. Anti-Mullerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome. Gynecol Endocrinol. 2013;29(9):826-9.

Amer SA, Li TC, Ledger WL. The value of measuring anti-Mullerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod. 2009;24(11):2760-6.

Aleyasin A, Aghahoseini M, Mokhtar S, Fallahi P. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients. Acta Med Iran. 2011;49(11):715-20.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45.

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9.

Chao KC, Ho CH, Shyong WY, Huang CY, Tsai SC, Cheng HY. Anti-Mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women. J Chin Med Assoc. 2012;75(2):70-4.

Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240(4857):1285-93.

Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83(7):2361-5.

Koninger A, Sauter L, Edimiris P, Kasimir-Bauer S, Kimmig R, Strowitzki T. Predictive markers for the FSH sensitivity of women with polycystic ovarian syndrome. Hum Reprod. 2014;29(3):518-24.

Pellatt L, Rice S, Mason HD. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010;139(5):825-33.

Catteau-Jonard S, Jamin SP, Leclerc A, Gonzales J, Dewailly D, di CN. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(11):4456-61.

Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA. The predictive value of circulating anti-Mullerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. J Clin Endocrinol Metab. 2013;98(10):4170-5.

El-Halawaty S, Rizk A, Kamal M, AboulHassan M, Al-Sawah H, Noah O. Clinical significance of serum concentration of anti-Mullerian hormone in obese women with polycystic ovary syndrome. Reprod BioMed Online. 2007;15(5):495-9.

Vaiarelli A, Drakopoulos P, Blockeel C, De VM, van d, V, Camus M. Limited ability of circulating anti-Mullerian hormone to predict dominant follicular recruitment in PCOS women treated with clomiphene citrate: a comparison of two different assays. Gynecol Endocrinol. 2015;1-4.

Kim JY, Yi G, Kim YR, Chung JY, Ahn JH, Uhm YK. Association between serum anti-Mullerian hormone level and ovarian response to mild stimulation in normoovulatory women and anovulatory women with polycystic ovary syndrome. Clin Exp Reprod Med. 2013;40(2):95-9.

Amer SA, Mahran A, Abdelmaged A, El-Adawy AR, Eissa MK, Shaw RW. The influence of circulating anti-Mullerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot study. Reprod Biol Endocrinol. 2013;11:115.

Desforges-Bullet V, Gallo C, Lefebvre C, Pigny P, Dewailly D, Catteau-Jonard S. Increased anti-Mullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril. 2010;94(1):198-204.

Falbo A, Rocca M, Russo T, D'Ettore A, Tolino A, Zullo F. Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res. 2010;3:16.

Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril. 2005;83(1):130-6.

La MA, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod. 2004;19(12):2738-41.

Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92(1):240-5.